178 related articles for article (PubMed ID: 33238958)
1. Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis.
Rumpold H; Niedersüß-Beke D; Heiler C; Falch D; Wundsam HV; Metz-Gercek S; Piringer G; Thaler J
BMC Cancer; 2020 Nov; 20(1):1149. PubMed ID: 33238958
[TBL] [Abstract][Full Text] [Related]
2. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.
Sjoquist KM; Renfro LA; Simes RJ; Tebbutt NC; Clarke S; Seymour MT; Adams R; Maughan TS; Saltz L; Goldberg RM; Schmoll HJ; Van Cutsem E; Douillard JY; Hoff PM; Hecht JR; Tournigand C; Punt CJA; Koopman M; Hurwitz H; Heinemann V; Falcone A; Porschen R; Fuchs C; Diaz-Rubio E; Aranda E; Bokemeyer C; Souglakos I; Kabbinavar FF; Chibaudel B; Meyers JP; Sargent DJ; de Gramont A; Zalcberg JR;
J Natl Cancer Inst; 2018 Jun; 110(6):638-648. PubMed ID: 29267900
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.
Fernández Montes A; López López C; Argilés Martínez G; Páez López D; López Muñoz AM; García Paredes B; Gutiérrez Abad D; Castañón López C; Jiménez Fonseca P; Gallego Plazas J; López Doldán MC; Martínez de Castro E; Sánchez Cánovas M; Tobeña Puyal M; Llorente Ayala B; Juez Martel I; López Flores M; Carmona-Bayonas A
Oncologist; 2019 Aug; 24(8):e687-e695. PubMed ID: 31147489
[TBL] [Abstract][Full Text] [Related]
4. [A prognostic nomogram for metastasized colorectal cancer patients treated with cetuximab].
Zhong LP; Li D; Zhu LZ; Fang XF; Xiao Q; Ding KF; Yuan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jul; 23(7):701-708. PubMed ID: 32683833
[No Abstract] [Full Text] [Related]
5. Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.
Loupakis F; Moretto R; Aprile G; Muntoni M; Cremolini C; Iacono D; Casagrande M; Ferrari L; Salvatore L; Schirripa M; Rossini D; De Maglio G; Fasola G; Calvetti L; Pilotto S; Carbognin L; Fontanini G; Tortora G; Falcone A; Sperduti I; Bria E
Br J Cancer; 2016 Jan; 114(1):30-6. PubMed ID: 26575603
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey.
Cakan B; Acikgoz O; Bilici A; Demir T; Basak Oven B; Hamdard J; Olmuscelik O; Olmez OF; Seker M; Yildiz O
J BUON; 2021; 26(5):1908-1917. PubMed ID: 34761599
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience.
Jin Z; Sanhueza CT; Johnson B; Nagorney DM; Larson DW; Mara KC; Harmsen WC; Smyrk TC; Grothey A; Hubbard JM
Oncologist; 2018 Sep; 23(9):1083-1091. PubMed ID: 29674439
[TBL] [Abstract][Full Text] [Related]
8. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer.
Huang CW; Tsai HL; Chen YT; Huang CM; Ma CJ; Lu CY; Kuo CH; Wu DC; Chai CY; Wang JY
BMC Cancer; 2013 Dec; 13():599. PubMed ID: 24330663
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of Lynch syndrome, BRAF
Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
[TBL] [Abstract][Full Text] [Related]
10. A validated prognostic classifier for
Loupakis F; Intini R; Cremolini C; Orlandi A; Sartore-Bianchi A; Pietrantonio F; Pella N; Spallanzani A; Dell'Aquila E; Scartozzi M; De Luca E; Rimassa L; Formica V; Leone F; Calvetti L; Aprile G; Antonuzzo L; Urbano F; Prenen H; Negri F; Di Donato S; Buonandi P; Tomasello G; Avallone A; Zustovich F; Moretto R; Antoniotti C; Salvatore L; Calegari MA; Siena S; Morano F; Ongaro E; Cascinu S; Santini D; Ziranu P; Schirripa M; Buggin F; Prete AA; Depetris I; Biason P; Lonardi S; Zagonel V; Fassan M; Di Maio M
Eur J Cancer; 2019 Sep; 118():121-130. PubMed ID: 31330487
[TBL] [Abstract][Full Text] [Related]
11. Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial.
Pietrantonio F; Fucà G; Manca P; Pagani F; Raimondi A; Prisciandaro M; Randon G; Corti F; de Braud F; Cremolini C; Miceli R
Tumori; 2021 Aug; 107(4):353-359. PubMed ID: 33021466
[TBL] [Abstract][Full Text] [Related]
12. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
Goey KKH; Elias SG; van Tinteren H; Laclé MM; Willems SM; Offerhaus GJA; de Leng WWJ; Strengman E; Ten Tije AJ; Creemers GM; van der Velden A; de Jongh FE; Erdkamp FLG; Tanis BC; Punt CJA; Koopman M
Ann Oncol; 2017 Sep; 28(9):2128-2134. PubMed ID: 28911067
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Ghiringhelli F; Bichard D; Limat S; Lorgis V; Vincent J; Borg C; Berthou J; Orry D; Ortega-Deballon P; Lakkis Z; Facy O; Heyd B; Rat P; Nerich V; Ladoire S
Ann Surg Oncol; 2014 May; 21(5):1632-40. PubMed ID: 24419756
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
van Rooijen KL; Shi Q; Goey KKH; Meyers J; Heinemann V; Diaz-Rubio E; Aranda E; Falcone A; Green E; de Gramont A; Sargent DJ; Punt CJA; Koopman M
Eur J Cancer; 2018 Mar; 91():99-106. PubMed ID: 29353165
[TBL] [Abstract][Full Text] [Related]
15. Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit.
Bertero L; Spadi R; Osella-Abate S; Mariani S; Castellano I; Gambella A; Racca P; Morino M; Cassoni P
World J Surg Oncol; 2020 Apr; 18(1):65. PubMed ID: 32241284
[TBL] [Abstract][Full Text] [Related]
16. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
17. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer.
Kattan MW; Gönen M; Jarnagin WR; DeMatteo R; D'Angelica M; Weiser M; Blumgart LH; Fong Y
Ann Surg; 2008 Feb; 247(2):282-7. PubMed ID: 18216534
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of primary tumor resection and lymph node dissection in stage IV colorectal cancer with unresectable metastasis: a propensity score analysis in a multicenter retrospective study.
Ishihara S; Hayama T; Yamada H; Nozawa K; Matsuda K; Miyata H; Yoneyama S; Tanaka T; Tanaka J; Kiyomatsu T; Kawai K; Nozawa H; Kanazawa T; Kazama S; Yamaguchi H; Sunami E; Kitayama J; Hashiguchi Y; Sugihara K; Watanabe T
Ann Surg Oncol; 2014 Sep; 21(9):2949-55. PubMed ID: 24763981
[TBL] [Abstract][Full Text] [Related]
19. Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status.
Kawaguchi Y; Kopetz S; Tran Cao HS; Panettieri E; De Bellis M; Nishioka Y; Hwang H; Wang X; Tzeng CD; Chun YS; Aloia TA; Hasegawa K; Guglielmi A; Giuliante F; Vauthey JN
Br J Surg; 2021 Aug; 108(8):968-975. PubMed ID: 33829254
[TBL] [Abstract][Full Text] [Related]
20. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
